269 related articles for article (PubMed ID: 35544598)
1. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.
Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
4. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
[TBL] [Abstract][Full Text] [Related]
7. Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia.
Ivanyi P; Morgan M; Piao W; Ukena SN; Steube K; Ganser A; Franzke A
Cell Oncol; 2010; 32(1-2):101-8. PubMed ID: 20208138
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
[TBL] [Abstract][Full Text] [Related]
9. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
13. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
[TBL] [Abstract][Full Text] [Related]
15. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.
Mestermann K; Giavridis T; Weber J; Rydzek J; Frenz S; Nerreter T; Mades A; Sadelain M; Einsele H; Hudecek M
Sci Transl Med; 2019 Jul; 11(499):. PubMed ID: 31270272
[TBL] [Abstract][Full Text] [Related]
17. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
[TBL] [Abstract][Full Text] [Related]
18. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
Nyakeriga AM; Garg H; Joshi A
Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine 192 within the SH2 domain of the Src-protein tyrosine kinase p56
Kästle M; Merten C; Hartig R; Kaehne T; Liaunardy-Jopeace A; Woessner NM; Schamel WW; James J; Minguet S; Simeoni L; Schraven B
Cell Commun Signal; 2020 Nov; 18(1):183. PubMed ID: 33225946
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
